Objectives : The present study was conducted to examine whether Toosendan Fructus has an ameliorative effect on diabetes-induced alterations such as oxidative stress and inflammation in the pancreas of non-obese diabetic (NOD) mice, a model of human type I diabetes.
Introduction 1)
Non-obese diabetic (NOD) mice, which develop type 1 diabetes (T1D) spontaneously, is very similar to the human disorder, insulin-dependent diabetes mellitus (IDDM). Accordingly, diabetes in NOD mice is the most extensively studied model of autoimmune disease 1, 2) . T1D is caused by the destruction of the insulin-producing β -cells through insulitis, which involves the infiltration of leukocytes into pancreatic islets 3, 4) . In addition, the development of insulitis lead to the excess accumulation of inflammatory cells, a gradual decrease in β -cells mass, and the development of chronic hyperglycemia 5) . Recently, various research on herbal medicine has been studied as an alternative medicine for prevention and treating diabetes 6) .
Toosendan Fructus is a fruit of Melia toosendan Sieb. is a widely known major component. Toosendanin has displayed apoptosis inducing activity 8) and suppressed proliferation of cancer cells 9) , anti-botulinum acivity 10) , anti-microbial activity 11) , inhibitory effect of releasing an acetylcholine 12) , activation of drug metabolic enzymes and bile juice release in the liver 13) , and anti-hyperlipidemia activity 14) . Recently two limonoids demonstrating antiinflammation and analgesic properties were reported 15) .
In addition, Toosendan Fructus (TF), a typical tranditional medicine, also reported antioxidative and anti-diabetic effect on blood glucose, lipid metabolism, and carbohydrate metabolism-related enzyme activities in the liver of streptozotocin-induced diabetic rats 7) . However, TF
has not reported anti-diabetic activity through the antiinflammatory activity in the pancreatic tissue of NOD mice.
Materials and Methods
Plant material
Toosendan Fructus was purchased from Omniherb 
Animals

Intraperitoneal glucose tolerance test (IPGTT)
Mice at 19 weeks of age (n = 8) were fasted for 12 h and then injected intraperitoneally with a single bolus of glucose (2 g/kg body weight) 16) . Glucose levels in blood collected from the tail vein were measured 0, 20, 40, 60, 90 and 120 min after glucose administration. Blood was immediately centrifuged (1,800 x g), the serum was separated and stored at -20 ℃ until assayed. 
Histopathological procedures and insulitis evaluation
Mice pancreases were fixed in 10% neutral buffered formalin, and then embedded in paraffin. Tissue sections (500 µm apart from each other) were deparaffinized, hydrolyzed and stained with hematoxylin and eosin. Islets in each section were assessed as described previously 17, 18) .
For histological scoring of insulitis, the sections were examined microscopically 19) . 
Statistical analysis
All data were expressed as means ± standard error Duncan's test was used to compare the data. Differences were considered significant at p < 0.05.
Results
Onset of type 1 diabetes and survival rate
The onset of diabetes mellitus (DM) was diagnosed when a mouse had glucose content of >300 mg/dl after fasting 4 h. Mouse deaths in the middle of the experiment were attributed to the incidence of DM because of the decreased weight induced by DM.
The DM onset ratios in the NOD control group were 58.3% at 17 weeks and 100% at 25 weeks. However, the onset ratios in the group treated with ETF at 50 mg/kg were 66.7% at 21 weeks, and 100% at 29 weeks; those in the group treated with ETF at 100 mg/kg were 50% at 17 weeks, and 100% at 33 weeks; those in the group treated ETF at 200 mg/kg were 41.7% at 17 weeks, and 100% at 33 weeks.
The survival rate of the normal group was 100% until the end of the experiment, whereas that of the 
Changes in blood glucose
Between 17 and 33 weeks, blood glucose levels were significantly increased in NOD mice in comparison with those in normal mice; those in the group treated ETF at 50 mg/kg tended to be lower than in the NOD control group, but the differences were not significant.
As shown in Table 1 , the group treated ETF at 100 mg/kg showed a significant decline in glucose level in comparison with NOD mice from 21 weeks, and the group treated ETF at 200 mg/kg showed significant decreases in glucose levels from 17 weeks( Table 1) . 
Changes in body weight, and food and water consumption
Body weight in the normal group was 17.7 ± 0.1 g at 5 weeks, and gradually increased to 36.5 ± 0.2 g at 33 weeks, whereas the NOD group showed significant body weight loss (26.0 ± 0.2 g at 21 weeks, and 22.4 ± 0.1 g at 33 weeks). Body weight in the group treated ETF respectively increased in comparison with the NOD control, especially in groups treated ETF at 100 mg/kg (25.6 ± 0.2 g) and 200 mg/kg (28.1 ± 0.2 g).
The water intake level of NOD mice was 0.173 ± 0.014 ml/g at 17 weeks, and was significantly higher than that of the normal group up to 33 weeks. In the groups treated ETF at 100 mg/kg and 200 mg/kg, water consumption was significantly lower than the NOD control. No significant changes in food intake were observed among NOD control and groups treated ETF( Table 2) . 
Changes in Total cholesterol (TC) and
Triglyceride (TG) in serum TC level was 88.5±7.8 mg/dl in normal group, 212.8 ± 17.6 mg/dl in NOD control, 209.0 ± 14.9 mg/dl in the group treated ETF at 50 mg/kg ETF, 187.6 ± 9.4 mg/dl in the group treated ETF at 100 mg/kg, and 173.1 ± 7.4 mg/dl in the group treated ETF at 200 mg/kg ETF. The values for the latter two groups were significantly lower than that in NOD control.
TG level in normal group was 2.6 ± 0.1 mg/dl, and was significantly increased (up to 5.8 ± 0.3 mg/dl) in NOD control. TG content in the groups treated with ETF at 100 mg/kg, 5.5 ± 0. mg/dl; 200 mg/kg, 5.1 ± 0.2 mg/dl), were significantly lower than in NOD control (Fig. 2) . 
Intraperitoneal glucose tolerance test
The levels of blood glucose in NOD and ETF treated group were significantly increased compared to that in the normal group at all time points. Glucose levels significantly decreased from 60 min to 120 min in group treated ETF at 100 mg/kg and 200 mg/kg compared to NOD control (Table 3, Fig. 3 ). 
Cytokine levels in serum
The inflammatory cytokines such as IFN-γ , IL-1β , IL-6 and IL-12 in NOD control were significantly increased in comparison with those of normal group. Administration of ETF significantly reduced the inflammation index, but the levels of anti-inflammatory cytokines (IL-4 and IL-10) were higher in the group treated ETF than in NOD control, but this differences were not significant (Table 4) . 
Western blot analysis of proteins in pancreatic tissue
The levels of iNOS and COX2 (proteins related to inflammation) in two ETF-treated groups (100 mg/kg and 200 mg/kg) were significantly lower than those in the NOD control group. ETF administration significantly increased the levels of SOD and catalase in the group treated ETF at 100 mg/kg and 200 mg/kg in comparison with that in NOD control (Fig. 4) . 
Insulitis evaluation
Photomicrographs of the pancreases showed a marked decrease in the number of islets of Langerhans, with atrophy of the islets, in the NOD control group. Histological examination showed that NOD mice at 33 weeks of age developed insulitis at various stages associated with lymphocyte infiltration. The average score of insulitis severity was similar between NOD controls and low-ETF-treated mice, whereas it was significantly lower in the medium-and high-ETF-treated groups than in the control group. These datas indicate that ETF treatment on NOD diabetes mouse inhibits a lymphocyte infiltration into pancreatic islets.
In all mice in the control and low-ETF-treated groups, various stages of lymphocyte infiltration were observed in submandibular glands, which was reduced in the medium-and high-ETF-treated groups. The severity of lymphocyte infiltration was lower in the high-ETF-treated group than in the control group (Fig. 5) . Lymphocyte infiltration was rarely observed in parotid or sublingual glands in all groups(data not shown). . IFN-γ is a mediator of islet β -cell destruction in vitro as well as β -cell-destructive insulitis and IDDM 21) . Our study showed that a release of IFN-γ dose-dependently were downregulated in NOD mice treated with ETF.
Correlation studies between cytokines expressed in the islets and autoimmune diabetes development in NOD mice and BB rats have demonstrated that beta-cell destructive insulitis is associated with increased expression of proinflammatory cytokines (IL-1, TNF-α , and IFN-γ ) and type 1 cytokines (IFN-γ , TNF-α , and IL-12), whereas non-destructive (benign) insulitis is associated with increased expression of type 2 cytokines (IL-4 and IL-10) and a type 3 cytokine (TGF-β ). Cytokines (IL-1, TNF-α , TNF-β and IFN-γ ) may be directly cytotoxic to β -cells by inducing nitric oxide and oxygen free radicals in the β -cells.
NOD mice with targeted deletions of IL-12 and IFN-γ genes still develop IDDM, albeit less often, and the onset of the disease is delayed. In contrast, post-natal deletion of IL-12 and IFN-γ , and also IL-1, TNF-α , IL-2, and IL-6 (by systemic administration of neutralizing antibodies, soluble receptors or receptor antagonists, or receptor-targeted cytotoxic drugs) significantly decreases IDDM incidence in NOD mice 22) .
Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of insulin-producing β -cells in the pancreatic islets of Langerhans. The autoimmune response against islet β -cells is believed to result from a disorder of immunoregulation. According to this concept, a T helper 1 (Th1) subset of T cells and their cytokine products, i.e. Type 1 cytokines (IFN-γ and TNF-α ), dominate over an immunoregulatory (suppressor) Th2 subset of T cells and their cytokine products, i.e. Type 2 cytokines (IL-4 and IL-10). This allows Type 1 cytokines to initiate a cascade of immune/inflammatory processes in the islets (insulitis), culminating in β -cell destruction. Type 1 cytokines activate (1) cytotoxic T cells that interact specifically with β -cells and destroy them, and (2) macrophages that produce proinflammatory cytokines (IL-1 and TNF-α ), as well as oxygen and nitrogen free radicals that are highly toxic to β -cells. Furthermore, IL-1, TNF-α , and IFN-γ are cytotoxic to β -cells, largely by inducing the formation of oxygen free radicals, nitric oxide, and peroxynitrite in these cells. Therefore, it would appear that prevention of β -cell destruction and IDDM should be aimed at stimulating the production and/or action of Type 2 cytokines, inhibiting the production and/or action of Type 1 cytokines, and inhibiting the production and/or action of oxygen and nitrogen free radicals in the pancreatic islets 23) . The nonspecific immune/inflammatory response involves β -cell destruction by T cell-and macrophage-derived proinflammatory cytokines (IL-1, TNF-α , TNF-β , IFN-γ ) and free radicals/oxidants, e.g. O2, H2O2, and NO. These inflammatory mediators are produced in T cells (both CD41 and CD81) and macrophages activated by cytokines (such as particularly IFN-γ , and also IL-2, TNF-α , and TNF-β ) in T cells.
In addition, mRNA levels of iNOS correlate with mRNA levels of IL-1α and IFN-γ in islets of prediabetic NOD mice, and iNOS protein is expressed in islet-infiltrating macrophages and β -cells 24) . These findings suggest that IL-1 (from macrophages) and IFN-γ (from T cells) induce iNOS and consequent NO production by macrophages and by β -cells. In this way, macrophage-derived NO would be destructive to adjacent β -cells, and β -cell-derived NO would be self-destructive. Indeed, NO has been identified as an important mediator of β -cell damage by activated macrophages 25) . Also, release of IL-1 in intraislet by passenger macrophage activation in vitro leads to iNOS expression in b-cells and consequent impaires insulin secretion 26) . The levels of iNOS in two ETF-treated groups (100 mg/kg and 200 mg/kg) were significantly lower than those in the NOD control group. Thus, avariety of antioxidants (deferoxamine, nicotinamide, SOD, α -tocopherol, probucol, and lazaroid) have been reported to provide some protection against IDDM development in autoimmune diabetes-prone BB rats and/or NOD mice [27] [28] [29] [30] [31] [32] [33] . ETF administration increased the levels of SOD and catalase compared to NOD control.
In the present study, blood glucose, hyperlipidemia, glucose resistance and water consumption were significantly reduced in the group treated ETF in comparison with NOD control group. This indicates that ETF reduces clinical symptoms of diabetes by protecting pancreatic β -cells from injury. We analyzed both proinflammatory and anti-inflammatory cytokines. The levels of proinflammatory cytokines in serum (IFN-γ , IL-1β , IL-6 and IL-12) were significantly lower than in NOD control, whereas the levels of anti-inflammatory cytokines (IL-4 and IL-10) were increased by ETF in a dose-dependent manner, although this effect did not reach statistical significance. To investigate the protective effect of ETF on β -cells, proinflammatory proteins (iNOS and COX2), antioxidant biomarkers (SOD and catalase) were analyzed by Western blotting. Cytokines such as IFN-γ , IL-1β , IL-6 and IL-12 induced oxidant stress to β -cell. ETF significantly decreased inflammatory proteins, and significantly increased SOD and catalase protein level in pancreas. In addition, proapoptic caspase-3 protein expression significantly suppressed in ETF 200 mg/kg. These results correspond to analysis of cytokines in serum and the histological insulitis score.
Conclusion
The present study was conducted to examine whether extracts of Toosendan Fructus (ETF) has an ameliorative effect on diabetes-induced alterations such as oxidative stress and inflammation in the pancreas of nonobese diabetic (NOD) mice, a model of human type 1 diabetes.
1. The administration of ETF delays the onset of type 1 diabetes and increase the survival rate dose-dependent manner in non-obese diabetic mice.
2. The administration of ETF showed significantly improved blood glucose levels and glucose tolerance.
3. The administration of ETF decreased proinflammatory cytokines, TG, and TC in serum.
4. The administration of ETF were significantly lower the levels of iNOS and COX2 (proteins related to inflammation) and increased the levels of SOD and catalase (proteins related to antioxidant).
5. The administration of ETF enhanced pancreatic insulitis through inhibiting lymphocyte infiltration into pancreatic islets.
We conclude that ETF could be a possible remedy for diabetes through and anti-oxidant effect and suppression of inflammation induced by oxidative stress in pancreatic β -cells. However, further studies are needed to elucidate the mechanism for this ETF action, which will provide valuable information for clinical trial to further evaluate its anti-diabetic potential in humans with type 1 diabetes
